An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors


Satya is a pre-clinical stage targeted oncology company, building a portfolio of complimentary therapeutics to address a wide range of tumors characterized by high replication stress. 

Targets have been carefully selected in the DDR and oncogene space for treating patients with prevalent or induced replication stress 

Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders. 

Scroll to Top